<DOC>
	<DOCNO>NCT02433717</DOCNO>
	<brief_summary>Background Paliperidone active metabolite risperidone , antipsychotic agent treatment schizophrenia relate psychotic disorder . Pharmacogenetic study reveal efficacy side effect antipsychotic agent related polymorphism specific gene , however , related study paliperidone . The current study aim evaluate whether pharmacogenetic marker relate risperidone genetic marker associate schizophrenia effect clinical effectiveness paliperidone treatment . The study also use change event-related potential ( ERP ) indices clinical efficacy . Methods It prospective , open-label , non-randomized uncontrolled clinical trial study efficacy side effect 6-week paliperidone ER treatment patient schizophrenia schizoaffective disorder . The first three week treatment inpatient treatment . In first two week , participant take 9 mg paliperidone ER daily . Then dose paliperidone adjust within range 6-12 mg per day . Efficacy indicator include symptom severity , global functioning , ERP . Side effect indicator include common side effect evaluate , extrapyramidal symptom , metabolic profile , hormonal change , bone metabolism index . Participants also receive examination blood drug concentration , genetic polymorphism , epigenetic marker .</brief_summary>
	<brief_title>A Pharmacokinetic Study Paliperidone ER</brief_title>
	<detailed_description>A . Background Schizophrenia heterogeneous disorder whose pathophysiology yet understood clearly . The treatment schizophrenia remain suboptimal . Take risperidone example , response rate patient around 60 % 80 % . The second-generation atypical antipsychotic widely use . Apart dopamine D2 receptor , also target 5-HT2 receptor receptor neurotransmission system . However , second-generation antipsychotic still result common side effect . Therefore , find predictor clinical efficacy side effect profile necessary task . Up date , several genetic non-genetic factor suggest related efficacy side effect antipsychotic . Noteworthy , pharmacokinetics indicate temporal change antipsychotic blood level usually overlook . It might contribute factor result pharmacogenetic study usually difficult replicate . Paliperidone ( 9-hydroxy-risperidone ) active metabolite second-generation antipsychotic risperidone . Pharmacogenetic study find polymorphism gene relate blood risperidone concentration , side effect treatment response . Comparing risperidone , paliperidone less metabolic side effect , probable fast occurrence efficacy , good tolerance subject hepatic insufficiency . Further , paliperidone sensitive P-glycoprotein . There pharmacogenetic study paliperidone P-glycoprotein . Therefore , one aim propose study examine pharmacogenetic effect paliperidone extend release ( paliperidone ER ) acute treatment schizophrenia schizoaffective disorder . The electrophysiological abnormality measure event-related potential ( ERP ) characteristic feature several neuropsychological disorder . For schizophrenia , deficit mismatch negativity , P50 , auditory steady state response frequently report . Therefore , besides clinical improvement , investigator also interest whether paliperidone treatment alter deficit mismatch negativity , P50 , ASSR . B . Study aim 1 . To study association candidate gene , related pharmacodynamics pharmacokinetics risperidone , paliperidone pharmacokinetics clinical response 2 . To evaluate impact pharmacodynamics efficacy ( include ERP change cognitive function ) side effect paliperidone ER acute treatment schizophrenia 3 . To evaluate whether paliperidone pharmacodynamics related metabolic , hormonal , bone turnover profile 4 . To evaluate whether paliperidone ER treatment influence epigenetic marker 5 . To evaluate whether paliperidone ER treatment influence event-related potential performance neurocognitive test C. Study design It 6-week , prospective , open-label , uncontrolled non-randomized trial paliperidone ER patient schizophrenia schizoaffective disorder acute episode . A total 40 subject recruit . D. Protocol overview : For least first three week , participant receive inpatient treatment acute psychiatry ward ( 03W2 ) National Taiwan University Hospital . Medication compliance , efficacy treatment side effect monitor evaluated psychiatrist principle investigator sub-investigators study . 1 . Dosage titration paliperidone ER : Fixed dose ( 9 mg/day ) paliperidone ER give first two week trial ( day 1 day 14 ) . Since third week ( day 15 ) , dosage adjust range 6 12 mg per day . 2 . Medication regulation : 1 . Antipsychotics paliperidone ER allow . 2 . For benzodiazepines sedatives/hypnotics : lorazepam 4 mg per day allow management medication withdrawal , side effect symptom . 3 . Anticholinergic agent : management extrapyramidal symptom biperiden 6 mg/day trihexyphenidyl 15 mg/day allow . 3 . Measurements 3-1 . Clinical evaluation day 0 , day 4 , day 7 , day14 , day 28 , day 42 : 1 . Efficacy evaluation : positive Negative Syndrome Scale ( PANSS ) , Personal Social Performance Scale ( PSP ) , Clinical Global Impression-Severity ( CGI-S ) 2 . Side effect evaluation : Drug-Induced Extrapyramidal Symptom Scale ( DIEPSS ) , Udvalg Kliniske Undersogelser ( UKU ) Side Effect Rating Scale ; new-onset adverse condition worsen original condition record side effect manage promptly . 3 . Body weight . 3-2 . Blood sample day 0 ( 40 ml ) , day 14 ( 15 ml ) day 42 ( 40 ml ) : 1 . Blood paliperidone concentration pharmacodynamics risperidone paliperidone day 0 , day 14 , day 42 . 2 . Blood biochemistry study ( AC sugar , uric acid , cholesterol , triglyceride , HDL-cholesterol , leptin , adiponectin , prolactin ) day 0 , day 14 , day 42 . 3 . Bone turnover marker ( serum alkaline phosphatase , calcium , phosphate bone-specific alkaline phosphatase , intact osteocalcin ) , hormonal marker ( oestradiol , progesterone , LH , FSH testosterone ) day 0 day 42 . 4 . DNA sample genetic marker day 0 : 1236C/T ABCB1 gene , Ser9Gly DRD3 gene , Ser311Cys DRD2 gene , 267T/C 5HTR6 gene , 102T/C 5HTR2A gene , 995G/A 5HTR2C gene , dinucleotide repeat ( GT ) n BDNF gene , val108/158Met COMT gene , polymorphisms RGS4 gene . 5 . Epigenetic marker day 0 day 42 . 3-3 . Urinary examination bone turnover marker day 0 day 42 : urinary deoxypyridinoline cross-link urinary C-terminal telopeptide fragment type I collagen 3-4 . Electrocardiogram day 0 day 42 . 3-5 . Event-related potential experiment day 0 day 42 : Participants receive experiment mismatch negativity , P50 auditory steady state response 3-6 . Neurocognitive test day 0 day 42 : Participants receive Continuous Performance Test ( CPT ) , Wisconsin Card Sorting Test ( WCST ) , Trail-A test , Trail-B test , verbal fluency test , select subtests Wechsler Adult Intelligence Test-III ( Digit Span Arithmetic ) . D. Conditions subject drop-out trial 1 . Whenever subject withdraws inform consent . 2 . Whenever serious treatment-emergent adverse event happen . 3 . Whenever treat psychiatrist principle investigator judge early dropout necessary subject , consider risk benefit clinically . 4 . Whenever subject violate trial protocol significant degree , judge treat psychiatrist principle investigator . E. Conditions trial stop Since paliperidone ER approve treatment schizophrenia Food Drug Administration daily dose within recommended range , trial terminate suspend follow situation : ( ) order Research Ethics Committee terminate suspend clinical trial ; ( b ) order Central Competent Health Authority terminate suspend clinical trial ; ( c ) paliperidone ER become unavailable National Taiwan University Hospital . F. Trial medication Paliperidone Extended-Release Tablets ( Invega ) : 9 mg/tab , 3 mg/tab G. Data collection statistical analysis Since current study open-labeled single-arm trial , aim prove efficacy paliperidone treatment schizophrenia . Instead , aim evaluate whether pharmacodynamics factor related clinical response paliperidone treatment . The variable clinical response define : 1 . Primary efficacy variable : response rate ( ratio subject respond paliperidone treatment ) . Response paliperidone treatment calculate [ ( PANSSevaluation - PANSSbaseline ) / ( PANSSbaseline -30 ) ] *100 % 2 . Secondary efficacy variable : PSP , CGI-S , ERPs neurocognitive test 3 . Side effect variable : DIEPSS , UKU side effect scale , body weight , blood chemistry marker , metabolic marker , hormonal marker , bone turnover marker Response rate efficacy variables analyze last observation carry forward intention-to-treat principle . Response rate calculate day 4 , 7 , 14 , 28 42 , impact pharmacodynamics genetic effect analyze accordingly . Demographic data , blood paliperidone concentration , aforementioned variable compare responder group non-responder group last visit ( Pearson χ2 test Fisher exact test use compare categorical variable ; independent test use continuous variable ) . The secondary efficacy side effect variable day 0 ( treatment ) day 42 ( treatment ) compare paired t-test . Relationship change aforementioned variable blood paliperidone concentration examine Pearson 's correlation coefficient test Spearman 's correlation coefficient test . Multiple linear regression analysis apply adjustment covariates . The genotyping quality check Hardy-Weinberg equilibrium test . Association allelic effect genetic marker clinical response outcome variable analyze use PLINK version 1.07 19 . Other statistical analysis perform use SAS®9.4 Software ( SAS Institute Inc. , USA ) . A p-value le 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Inclusion criterion : 2065 year old With DSMIV diagnosis schizophrenia schizoaffective disorder Being hospitalize acute psychiatric ward Scoring least 60 accord Positive Negative Syndrome Scale ( PANSS ) Having receive longacting injectable antipsychotic past 6 month Having major physical disorder significant abnormality laboratory study Exclusion criterion : Having abuse illicit substance past 6 month Having physical disorder may influence absorption , metabolism , excretion paliperidone ER With substantial suicidal violence risk Being pregnant lactating , high probability get pregnant With significant central nervous system abnormality With significant unstable incurable physical illness Having ever take clozapine past 3 month Having ever take paliperidone ER within 30 day eligibility evaluation History allergy paliperidone ER risperidone Without competence sign inform consent Hearing impairment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>schizoaffective disorder</keyword>
	<keyword>pharmacogenetics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>event-related potential</keyword>
	<keyword>paliperidone</keyword>
</DOC>